Shield Therapeutics (LON:STX) Stock Price Down 8.2% – Time to Sell?

Shield Therapeutics plc (LON:STX)’s stock price was down 8.2% on Wednesday . The stock traded as low as GBX 2.30 ($0.03) and last traded at GBX 2.47 ($0.03). Approximately 340,861 shares changed hands during mid-day trading, a decline of 86% from the average daily volume of 2,433,621 shares. The stock had previously closed at GBX 2.69 ($0.04).

Shield Therapeutics Stock Down 5.6%

The company’s 50 day moving average price is GBX 2.69 and its two-hundred day moving average price is GBX 2.84. The company has a current ratio of 1.05, a quick ratio of 2.16 and a debt-to-equity ratio of 3,691.50. The stock has a market cap of £22.35 million, a P/E ratio of -0.58 and a beta of 1.42.

Shield Therapeutics (LON:STX) last released its earnings results on Thursday, April 24th. The company reported GBX (3) (($0.04)) earnings per share (EPS) for the quarter. Shield Therapeutics had a negative return on equity of 470.50% and a negative net margin of 173.43%. Equities analysts forecast that Shield Therapeutics plc will post 0.0707619 earnings per share for the current year.

About Shield Therapeutics

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.